Nicholas Investment Partners, LP - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 204 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2015. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.

Quarter-by-quarter ownership
Nicholas Investment Partners, LP ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2015$3,669,000
-24.4%
15,202
-11.6%
0.24%
-22.4%
Q1 2015$4,850,000
+139.4%
17,196
+32.4%
0.30%
+138.6%
Q4 2014$2,026,000
+88.5%
12,987
+185.9%
0.13%
+89.6%
Q3 2014$1,075,000
-42.7%
4,542
-42.7%
0.07%
-39.1%
Q2 2014$1,876,0007,9260.11%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2015
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$14,787,0002.73%
DeepCurrents Investment Group LLC 416,800$9,620,0000.33%
DUALITY ADVISERS, LP 105,668$2,439,0000.21%
EULAV Asset Management 335,000$7,732,0000.21%
Virtus ETF Advisers LLC 19,375$447,0000.19%
Hennion & Walsh Asset Management, Inc. 135,214$3,121,0000.19%
PDT Partners, LLC 110,592$2,552,0000.18%
KETTLE HILL CAPITAL MANAGEMENT, LLC 70,256$1,622,0000.16%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$3,896,0000.12%
WOODWARD DIVERSIFIED CAPITAL, LLC 8,939$206,0000.12%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders